ImPact Biotech Presents Updated Data from Phase 3 ENLIGHTED Trial of Padeliporfin VTP in LG-UTUC at AUA 2026
– Complete response (CR) observed in 70% (50/72) of evaluable patients with…
BugleRock Capital’s Global AUA Surpasses $4 Billion USD
Launches Fixed Income Advisory Services with Expert Team BENGALURU, India, July 8,…
